0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

Spruce Biosciences Touts MPS IIIB Data, Targets Q4 BLA Submission at Oppenheimer Conference [Yahoo! Finance]

BioMarin Pharmaceutical Inc. (BMRN)  More Company Research Source: Yahoo! Finance
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
considerations for the company's lead program in Sanfilippo syndrome type B (MPS IIIB) during a fireside chat at Oppenheimer's 36th Annual Healthcare and Life Sciences Conference. Program overview and development history Chief Executive Officer Dr. Javier Szwarcberg discussed Spruce's enzyme replacement therapy program, referred to in the discussion as “TA-ERT,” which is designed for central nervous system (CNS) delivery. Unlike most enzyme replacement therapies that are administered intravenously and have limited penetration into the brain, Szwarcberg said this therapy is administered directly into the cerebrospinal fluid (CSF) via intracerebroventricular (ICV) delivery using an Ommaya reservoir. He said this approach is intended to address the profound CNS involvement in neuronopathic forms of mucopolysaccharidoses, including MPS IIIB. ? AI Is Separating Software Winners From Losers, 2 Experts Explain Szwarcberg said the therapy was originally developed at BioMarin as a fusi [Read more]
IMPACT SNAPSHOT EVENT TIME: BMRN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
BMRN alerts
from News Quantified
BMRN
NEWS
BMRN
Earnings
BMRN
Analyst Actions
BMRN
SEC Filings
Stockreport

Spruce Biosciences Touts MPS IIIB Data, Targets Q4 BLA Submission at Oppenheimer Conference [Yahoo! Finance]

BioMarin Pharmaceutical Inc.  (BMRN) 
More Company Research Source: Yahoo! Finance
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
considerations for the company's lead program in Sanfilippo syndrome type B (MPS IIIB) during a fireside chat at Oppenheimer's 36th Annual Healthcare and Life Sciences Conference. Program overview and development history Chief Executive Officer Dr. Javier Szwarcberg discussed Spruce's enzyme replacement therapy program, referred to in the discussion as “TA-ERT,” which is designed for central nervous system (CNS) delivery. Unlike most enzyme replacement therapies that are administered intravenously and have limited penetration into the brain, Szwarcberg said this therapy is administered directly into the cerebrospinal fluid (CSF) via intracerebroventricular (ICV) delivery using an Ommaya reservoir. He said this approach is intended to address the profound CNS involvement in neuronopathic forms of mucopolysaccharidoses, including MPS IIIB. ? AI Is Separating Software Winners From Losers, 2 Experts Explain Szwarcberg said the therapy was originally developed at BioMarin as a fusi [Read more]
IMPACT SNAPSHOT
EVENT TIME:
BMRN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS